Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

14.0K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
14.0K
Blood Transfusion01:15

Blood Transfusion

2.1K
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
2.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same authorSame journal

Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study.

Blood vessels, thrombosis & hemostasis·2026
Same author

External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities.

Molecular therapy. Advances·2026
Same author

Targeting synovitis by immunomodulation as a novel therapeutic approach for hemophilic arthropathy.

Journal of thrombosis and haemostasis : JTH·2026
Same author

A novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial.

Bioelectronic medicine·2026
Same author

Inhibition of activated protein C anticoagulant function enhances coagulation but does not interrupt downstream mechanisms driving hemophilic arthropathy.

Experimental hematology·2026
Same author

Building a gene editing lexicon: a model for rare and inherited disorders.

Gene therapy·2026
Same journal

NETs contribute to acute episodes but not ADAMTS13 relapses in immune-mediated thrombotic thrombocytopenic purpura.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Immune-mediated acute thrombocytopenia within 30 minutes of first obinutuzumab infusion.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Successful eltrombopag discontinuation in paraneoplastic immune thrombocytopenia: a case report.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model.

Blood vessels, thrombosis & hemostasis·2026
Same journal

Impact of ABO blood groups on residual pulmonary vascular obstruction in patients with unprovoked pulmonary embolism.

Blood vessels, thrombosis & hemostasis·2026
查看所有相关文章

相关实验视频

Updated: Jan 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.6K

血液失调研究协作研究团队

Leonard A Valentino1, Maria E Santaella2, Michelle L Witkop2

  • 1Department of Pediatrics, Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL.

Blood vessels, thrombosis & hemostasis
|October 10, 2025
PubMed
概括
此摘要是机器生成的。

血液疾病研究协作 (BDRC) 通过研究,基础设施和社区合作伙伴关系,促进对遗传性血液疾病的护理. 它优先考虑健康公平和生活经验专业知识,以改善生活质量.

更多相关视频

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.4K
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.4K

相关实验视频

Last Updated: Jan 15, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.6K
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.4K
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.4K

科学领域:

  • 血液学 血液学 血液学
  • 公共卫生 公共卫生
  • 医疗保健服务研究 医疗服务研究

背景情况:

  • 遗传性出血障碍影响着众多个体,需要提高护理标准.
  • 目前的研究基础设施和劳动力能力可能无法完全满足这个社区的需求.
  • 卫生公平,多样性和包容性对于改善出血障碍管理结果至关重要.

研究的目的:

  • 建立出血障碍研究合作组织 (BDRC),作为推进遗传性出血障碍治疗的典范.
  • 促进合作的科学研究,并建立一个高效的研究基础设施.
  • 促进健康公平,多样性,包容性和社区参与出血障碍研究.

主要方法:

  • 建立一个合作研究网络,专注于遗传性出血障碍.
  • 发展一个协调和高效的研究基础设施.
  • 与受影响社区合作,吸引多元化和有能力的劳动力.
  • 整合健康公平,多样性,包容性,可访问性和归属性的原则.
  • 在整个研究过程中纳入实践经验专家.

主要成果:

  • 该BDRC倡议建立在健康平等,多样性,包容性和归属性的原则之上.
  • 经验丰富的专家是研究开发,实施和传播的组成部分.
  • 一个可访问的护理标准和改善生活质量的框架正在推进.
  • 协作科学调查由一个高效的研究基础设施协调.

结论:

  • BDRC有望显著提高遗传性出血障碍患者的护理标准和生活质量.
  • 合作模式强调健康公平和社区伙伴关系,为健康正义提供了一条途径.
  • 实践经验专家的整合确保研究对出血障碍社区具有相关性和影响力.